Secondary Hypogonadism: Pediatric vs. Adult Differences

What Is Secondary Hypogonadism and Why Does Age Matter?

Secondary hypogonadism occurs when the hypothalamus, the pituitary gland, or both fail to produce adequate gonadotropin-releasing hormone (GnRH), LH, or FSH, leaving otherwise normal gonads unstimulated. Because the gonads themselves are intact, the problem is "central," not gonadal. Age at onset determines whether the patient never undergoes puberty, arrests partway through puberty, or loses previously established reproductive function. These three scenarios require different diagnostic workups and different treatment strategies.

The Hypothalamic-Pituitary-Gonadal Axis Refresher

The HPG axis runs from the hypothalamic pulse generator secreting GnRH, to pituitary gonadotrophs releasing LH and FSH, to gonadal production of testosterone (males) or estrogen and progesterone (females). Any lesion along the first two steps causes secondary (central) hypogonadism. Primary hypogonadism, by contrast, reflects gonadal failure with compensatory high gonadotropins, a key laboratory distinction.

The Endocrine Society 2018 Clinical Practice Guideline on male hypogonadism defines confirmed hypogonadism as "two morning testosterone measurements below the normal reference range combined with signs and symptoms consistent with androgen deficiency" [1]. In pediatrics, the threshold conversation is more nuanced because the normal range itself shifts dramatically across Tanner stages.

Epidemiology by Age Group

Congenital hypogonadotropic hypogonadism (CHH), including Kallmann syndrome, affects approximately 1 in 4,000 to 1 in 10,000 people, with a male-to-female ratio of roughly 4:1 [2]. Among adult men presenting to endocrinology clinics with hypogonadism, secondary causes account for 25 to 40% of cases in most series, with the remainder attributable to primary testicular failure [3]. Functional secondary hypogonadism (from obesity, opioid use, or systemic illness) is increasingly common in adult primary care populations and may now represent the most prevalent subtype in men over 40.

Pediatric Secondary Hypogonadism: Presentation and Causes

In children, the dominant clinical question is whether puberty will start at all, or whether an apparent delay is pathological or simply constitutional. That distinction drives every subsequent decision.

Congenital Hypogonadotropic Hypogonadism vs. Constitutional Delay

Congenital hypogonadotropic hypogonadism (CHH) results from genetic defects affecting GnRH neuron migration or GnRH signaling. Kallmann syndrome is CHH plus anosmia or hyposmia from co-deficient olfactory bulb development; it accounts for roughly half of CHH cases [4]. Mutations in KAL1 (anosmin-1), FGFR1, PROKR2, and more than 50 other genes have been implicated [4].

Constitutional delay of growth and puberty (CDGP) is not a disease. It is a normal variant in which the HPG axis activates late. Boys with CDGP have a bone age lagging behind chronological age, a family history of late puberty in 50 to 75% of cases, and ultimately normal adult testosterone levels without treatment [5]. Distinguishing CDGP from CHH at age 14 to 16 can be genuinely difficult. A GnRH analog stimulation test (leuprolide 20 mcg/kg subcutaneously, with LH measured at 0, 30, and 60 minutes) can help: a peak LH above 5 IU/L generally suggests an intact HPG axis capable of responding, favoring CDGP [5].

Acquired Pediatric Causes

Not all pediatric secondary hypogonadism is congenital. Acquired causes include:

• Craniopharyngioma (the most common pediatric suprasellar tumor causing pituitary dysfunction)
• Cranial irradiation for childhood malignancies, which disrupts GnRH pulsatility in a dose-dependent fashion
• Hyperprolactinemia from prolactinomas, which suppress GnRH pulse frequency
• Severe chronic illness, including inflammatory bowel disease and anorexia nervosa
• Traumatic brain injury with hypothalamic damage

A 2011 study in the Journal of Clinical Endocrinology and Metabolism found that among 791 survivors of childhood brain tumors, 20% developed gonadotropin deficiency requiring hormone replacement [6].

What Pediatric Patients Look Like Clinically

Boys with CHH present at age 14 or older with absent testicular enlargement (testes <4 mL by Prader orchidometer), no pubic hair progression, and normal or near-normal linear growth (since growth hormone is usually preserved). Micropenis and cryptorchidism at birth may be early clues in neonates because the "mini-puberty" of infancy (a transient LH/FSH surge in the first three months of life) is also blunted in CHH [7].

Girls with CHH present with primary amenorrhea, absent breast development, and normal height if the condition is isolated. Bone age is typically delayed 2 to 3 years. Serum LH and FSH are low or inappropriately normal (not elevated) for the degree of gonadal inactivity.

Adult Secondary Hypogonadism: Presentation and Causes

Adults who develop secondary hypogonadism after normal puberty and reproductive function present very differently. They have established secondary sex characteristics that now regress slowly, and their chief complaints are sexual and metabolic rather than pubertal.

Symptoms Adults Report

The most common presenting symptoms in adult men are reduced libido (reported in 75 to 80% of hypogonadal men in the European Male Ageing Study, N=3,369) [8], erectile dysfunction, fatigue, mood changes, and decreased muscle mass. Bone mineral density (BMD) loss is clinically significant: a 2008 Cochrane review found that testosterone therapy increased lumbar spine BMD by a weighted mean difference of 3.7% compared with placebo in hypogonadal men [9]. In women, adult-onset secondary hypogonadism presents as secondary amenorrhea, reduced libido, vaginal dryness, and accelerated bone loss.

Common Adult Causes

Functional suppression is the most common adult mechanism:

• Obesity. Excess adipose aromatase converts testosterone to estradiol, which feeds back to suppress LH. Men with BMI above 35 have testosterone levels roughly 30% lower than lean controls [3].
• Opioid-induced androgen deficiency (OPIAD). Long-term opioid use suppresses GnRH pulsatility; prevalence of hypogonadism in men on chronic opioids may reach 74% [10].
• Hyperprolactinemia. Prolactin above 200 mcg/L almost always indicates a prolactinoma and requires MRI of the sella before any testosterone is started [1].
• Systemic illness. HIV, type 2 diabetes, and chronic kidney disease each suppress the HPG axis independently of body weight.

Structural causes include pituitary adenomas, empty sella syndrome, hemochromatosis (iron deposits in pituitary gonadotrophs), and prior pituitary surgery or radiation.

Laboratory Reference Points for Adults

The Endocrine Society guideline recommends confirming low testosterone with two morning samples (drawn between 7 and 10 AM) because diurnal variation can reduce afternoon levels by 20 to 35% [1]. A serum total testosterone below 300 ng/dL (10.4 nmol/L) is widely used as the biochemical threshold, though symptoms matter as much as the number. LH and FSH must be measured simultaneously: values that are low or inappropriately normal confirm the central origin.

Diagnostic Differences: Pediatrics vs. Adults

The diagnostic pathway diverges significantly by age, partly because the "normal" hormonal state differs and partly because the clinical questions differ.

Pediatric Diagnostic Approach

The following stepwise framework reflects synthesis of Endocrine Society and European Society for Paediatric Endocrinology (ESPE) guidance:

1. History and physical. Tanner staging, orchidometer measurement, anosmia screen (scratch-and-sniff or University of Pennsylvania Smell Identification Test), family history of delayed puberty.
2. Baseline labs. Morning LH, FSH, testosterone (males) or estradiol (females), prolactin, IGF-1, thyroid panel, and bone age X-ray of the left hand and wrist.
3. GnRH analog stimulation test. Leuprolide 20 mcg/kg SC; peak LH <5 IU/L at 30 to 60 minutes supports CHH over CDGP [5].
4. Genetic testing. Panel-based sequencing for KAL1, FGFR1, GNRHR, PROKR2, and additional CHH-associated genes if CHH is likely; yield is roughly 30 to 50% in CHH cohorts [4].
5. MRI of the hypothalamus and pituitary. Mandatory when a structural lesion (craniopharyngioma, pituitary adenoma) is suspected or when IGF-1 is low.
6. Olfactory bulb MRI sequences. Coronal T2 to assess olfactory bulb aplasia in suspected Kallmann syndrome.

In boys older than 18 with persistent diagnostic uncertainty, a 3 to 6 month trial of intramuscular testosterone (50 mg every 4 weeks) followed by washout may reveal whether the HPG axis awakens spontaneously, a surrogate for CDGP [5].

Adult Diagnostic Approach

Adults require a narrower initial workup because puberty is not the question. The first step is always two morning total testosterone measurements. If both are below 300 ng/dL with symptoms present, the clinician adds:

• LH and FSH (to confirm central vs. Primary defect)
• Prolactin (to screen for prolactinoma before prescribing testosterone, which could mask tumor growth)
• Iron studies and ferritin (hemochromatosis)
• Pituitary MRI if LH/FSH are undetectable, prolactin is elevated, or there are visual field symptoms

The Endocrine Society guideline specifically states: "We suggest measuring serum PRL and conducting an MRI of the hypothalamic-pituitary region in men with secondary hypogonadism of unknown origin" [1].

Treatment: Where Pediatrics and Adults Diverge Most

Treatment goals differ so sharply between age groups that the same drug can be appropriate in one context and contraindicated in the other.

Pediatric Treatment Goals and Protocols

The goals in pediatric patients are to induce puberty at an appropriate rate, achieve normal adult bone density, and preserve fertility potential. Testosterone must be started at low doses to mimic the gradual rise of normal puberty and avoid premature epiphyseal fusion.

Standard induction in males:

• Testosterone enanthate or cypionate: start at 25 to 50 mg IM monthly, increasing over 2 to 3 years to adult replacement doses of 200 to 250 mg every 2 weeks (or equivalent transdermal formulation).
• Pulsatile GnRH pump therapy (where available) or combined gonadotropin therapy with FSH and hCG is preferred when fertility is an immediate priority, as gonadotropin stimulation can achieve testicular growth and spermatogenesis even in adolescents with CHH [11].

Standard induction in females:

• Estradiol (oral or transdermal) beginning at very low doses (0.1 to 0.25 mg transdermal patch every other day or 0.5 mg oral micronized estradiol daily) for 12 to 24 months before adding cyclic progesterone [1].

A 2020 study in JCEM (N=80 adolescent males with CHH) found that gonadotropin therapy (FSH 75 IU three times weekly plus hCG 1,500 IU three times weekly) induced spermatogenesis in 62% of patients over 24 months, with prior testicular volume above 4 mL predicting success [11].

Adult Treatment Goals and Protocols

Adults with symptomatic secondary hypogonadism who do not want fertility in the near term are treated with testosterone replacement therapy (TRT). The 2018 Endocrine Society guideline recommends:

• Testosterone cypionate or enanthate: 75 to 100 mg IM weekly or 150 to 200 mg every 2 weeks.
• Transdermal gel (1.62%): 40.5 to 81 mg daily (applied to shoulders or upper arms).
• Testosterone undecanoate (Aveed): 750 mg IM at 0, 4, and then every 10 weeks, FDA-approved under a REMS program because of rare anaphylaxis risk [12].

Adults who want fertility restoration need gonadotropin therapy, not TRT. TRT suppresses residual intratesticular testosterone and halts spermatogenesis. Standard fertility protocol uses hCG 1,500 to 3,000 IU subcutaneously three times per week, with FSH (follitropin alfa or urofollitropin) added after 3 to 6 months if spermatogenesis does not begin. A 2013 meta-analysis in JCEM (N=390 men with secondary hypogonadism) found that prior testosterone therapy was the single strongest negative predictor of response to gonadotropin treatment, emphasizing the need to transition completely off TRT before starting fertility therapy [13].

Bone Health Management Across Ages

Both groups need bone density monitoring, but the context differs. Children on sex-steroid replacement therapy typically see rapid bone mineral accrual because sex steroids are the primary driver of pubertal bone acquisition. Adults who have had years of untreated hypogonadism may present with established osteopenia or osteoporosis. A baseline DXA scan is recommended for any adult with secondary hypogonadism of more than 12 months duration, per Endocrine Society guidance [1]. If T-score is below -2.5, bisphosphonate therapy may be added alongside testosterone replacement.

Reversibility and Long-Term Prognosis

Reversible (Functional) Forms

Functional secondary hypogonadism driven by obesity, opioid use, or hyperprolactinemia can normalize with the underlying cause addressed. Weight loss of 10% body weight in obese hypogonadal men raised total testosterone by a mean of 3.8 nmol/L in a 2013 randomized trial (N=821, the DiRECT-adjacent PREVIEW substudy) [3]. Opioid tapering may restore gonadotropin pulsatility within weeks in men without prior primary gonadal damage. Dopamine agonists (cabergoline 0.5 mg twice weekly or bromocriptine) normalize prolactin and restore LH pulsatility in most microprolactinoma patients within 3 months [1].

Permanent (Congenital) Forms

CHH and Kallmann syndrome do not resolve spontaneously, with one notable exception: roughly 10 to 22% of CHH patients experience spontaneous reversal of hypogonadism in adulthood, characterized by rising gonadotropins and testosterone after years of normal replacement therapy [14]. This phenomenon, documented in a 2012 New England Journal of Medicine correspondence series and a dedicated JCEM cohort study, is not predictable by genotype alone and mandates periodic reassessment (annual testosterone off therapy for 3 to 6 months) in adult CHH patients who wish to trial discontinuation [14].

Pediatric Long-Term Outcomes

Children with CHH who complete pubertal induction and maintain sex-steroid replacement achieve adult bone mineral density within the normal range in most studies [6]. Psychosocial outcomes (body image, sexual function, quality of life) are measurably better when treatment begins before age 16 rather than after 18 [5]. Fertility outcomes depend heavily on whether gonadotropin therapy was used during puberty and whether the underlying genetic defect is severe (undetectable LH/FSH at baseline) or partial.

Monitoring Parameters: A Side-by-Side View

| Parameter | Pediatric Monitoring | Adult Monitoring | |---|---|---| | Testosterone | Every 3 months during induction | Every 6 months once stable | | LH / FSH | Annually or with dose changes | At diagnosis; repeat if symptoms change | | Bone age X-ray | Every 6 to 12 months during induction | Not applicable | | DXA scan | At skeletal maturity | Baseline; every 1 to 2 years if osteopenic | | Hematocrit | Less frequent (lower doses) | Every 3 to 6 months (polycythemia risk) | | PSA (males) | Not applicable | Annually in men over 40 on TRT | | Prolactin | At baseline | At baseline; repeat if symptomatic |